Global Cancer Anorexia-Cachexia Syndrome Drug

Cancer Anorexia-Cachexia Syndrome Drug Comprehensive Study by Type (NEO-1940, C-1889, DLN-101, Foxo1-nRNA, AVGN-7, Others), Mechanism of Action (Appetite Stimulators, Weight Loss Stabilizers), Therapeutics (Progestogens, Megestrol, Corticosteroids), End-User (Hospital, Clinic, OPDs, Others) Players and Region - Global Market Outlook to 2028

Cancer Anorexia-Cachexia Syndrome Drug Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Cancer Anorexia-Cachexia Syndrome Drug
Cancer anorexia-cachexia syndrome (CACS) is a multifactorial condition marked by progressive wasting. The loss of both skeletal muscle and fat distinguishes it from hunger. It's a metabolic syndrome in which glucose, protein, and lipid metabolism are all disrupted. Multifactorial pathophysiology has made some progress in recent years. Cancer syndrome is assumed to be the outcome of imbalanced interactions between inflammatory cytokines, neuropeptides, hormones, and tumor-derived substances, even though the etiology is unknown.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


Mergers and acquisitions, expansions, investments, new service launches, and collaborations are some of the companies' preferred market-exploration strategies. Players are expanding and acquiring businesses in new geographies to get a competitive edge through synergy. The major key players are contributing their share to increasing company growth. Industry leaders have improved their market position by investing more in research and having a more efficient distribution system. In December 2020, the University of Copenhagen, in partnership with Zealand University Hospital, began a clinical investigation on the effect of medical cannabidiol on lean body mass (cachexia) in patients receiving Oxaliplatin- or Paclitaxel-based chemotherapy. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Acacia Pharma Ltd (United Kingdom), Aeterna Zentaris Inc (United States), Aphios Corp (United Kingdom), Novartis AG (Switzerland), Incyte Corp (United States), Lakewood-Amedex Inc (United States), Obexia AG (Switzerland), PsiOxus Therapeutics Ltd (United Kingdom), RaQualia Pharma Inc (Japan) and Viking Therapeutics Inc (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Cancer Anorexia-Cachexia Syndrome Drug market by Type (NEO-1940, C-1889, DLN-101, Foxo1-nRNA, AVGN-7 and Others) and Region.



On the basis of geography, the market of Cancer Anorexia-Cachexia Syndrome Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Mechanism of Action, the sub-segment i.e. Appetite Stimulators will boost the Cancer Anorexia-Cachexia Syndrome Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapeutics, the sub-segment i.e. Progestogens will boost the Cancer Anorexia-Cachexia Syndrome Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Hospital will boost the Cancer Anorexia-Cachexia Syndrome Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Appetite Stimulators are expected to Grow Significantly

Market Growth Drivers:
Increasing prevalence of cancer and novel therapies and Rising pipeline products for cachexia cancer and increasing geriatric population

Challenges:
Limited reimbursement policies and stringent government regulations

Restraints:
High costs associated with treatment

Opportunities:
Many major players are focused on R&D activities to develop highly effective novel drugs and The potential of reversing drug resistance

In April 2021, Actimed therapeutics ltd announced a license agreement with faraday pharmaceuticals for S-oxprenolol. Under the terms of the agreement, the company will be eligible for royalties on any future S-oxprenolol sales, and faraday will have the global rights to develop and commercialize S-oxprenolol for cancer cachexia.


Key Target Audience
Cancer Anorexia-Cachexia Syndrome Drug Manufacturers, Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Traders/Suppliers & Distributors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • NEO-1940
  • C-1889
  • DLN-101
  • Foxo1-nRNA
  • AVGN-7
  • Others
By Mechanism of Action
  • Appetite Stimulators
  • Weight Loss Stabilizers

By Therapeutics
  • Progestogens
  • Megestrol
  • Corticosteroids

By End-User
  • Hospital
  • Clinic
  • OPDs
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of cancer and novel therapies
      • 3.2.2. Rising pipeline products for cachexia cancer and increasing geriatric population
    • 3.3. Market Challenges
      • 3.3.1. Limited reimbursement policies and stringent government regulations
    • 3.4. Market Trends
      • 3.4.1. Appetite Stimulators are expected to Grow Significantly
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Anorexia-Cachexia Syndrome Drug, by Type, Mechanism of Action, Therapeutics, End-User and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cancer Anorexia-Cachexia Syndrome Drug (Value)
      • 5.2.1. Global Cancer Anorexia-Cachexia Syndrome Drug by: Type (Value)
        • 5.2.1.1. NEO-1940
        • 5.2.1.2. C-1889
        • 5.2.1.3. DLN-101
        • 5.2.1.4. Foxo1-nRNA
        • 5.2.1.5. AVGN-7
        • 5.2.1.6. Others
      • 5.2.2. Global Cancer Anorexia-Cachexia Syndrome Drug by: Mechanism of Action (Value)
        • 5.2.2.1. Appetite Stimulators
        • 5.2.2.2. Weight Loss Stabilizers
      • 5.2.3. Global Cancer Anorexia-Cachexia Syndrome Drug by: Therapeutics (Value)
        • 5.2.3.1. Progestogens
        • 5.2.3.2. Megestrol
        • 5.2.3.3. Corticosteroids
      • 5.2.4. Global Cancer Anorexia-Cachexia Syndrome Drug by: End-User (Value)
        • 5.2.4.1. Hospital
        • 5.2.4.2. Clinic
        • 5.2.4.3. OPDs
        • 5.2.4.4. Others
      • 5.2.5. Global Cancer Anorexia-Cachexia Syndrome Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Cancer Anorexia-Cachexia Syndrome Drug (Price)
      • 5.3.1. Global Cancer Anorexia-Cachexia Syndrome Drug by: Type (Price)
  • 6. Cancer Anorexia-Cachexia Syndrome Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Acacia Pharma Ltd (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Aeterna Zentaris Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Aphios Corp (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Incyte Corp (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lakewood-Amedex Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Obexia AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. PsiOxus Therapeutics Ltd (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. RaQualia Pharma Inc (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Viking Therapeutics Inc (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cancer Anorexia-Cachexia Syndrome Drug Sale, by Type, Mechanism of Action, Therapeutics, End-User and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cancer Anorexia-Cachexia Syndrome Drug (Value)
      • 7.2.1. Global Cancer Anorexia-Cachexia Syndrome Drug by: Type (Value)
        • 7.2.1.1. NEO-1940
        • 7.2.1.2. C-1889
        • 7.2.1.3. DLN-101
        • 7.2.1.4. Foxo1-nRNA
        • 7.2.1.5. AVGN-7
        • 7.2.1.6. Others
      • 7.2.2. Global Cancer Anorexia-Cachexia Syndrome Drug by: Mechanism of Action (Value)
        • 7.2.2.1. Appetite Stimulators
        • 7.2.2.2. Weight Loss Stabilizers
      • 7.2.3. Global Cancer Anorexia-Cachexia Syndrome Drug by: Therapeutics (Value)
        • 7.2.3.1. Progestogens
        • 7.2.3.2. Megestrol
        • 7.2.3.3. Corticosteroids
      • 7.2.4. Global Cancer Anorexia-Cachexia Syndrome Drug by: End-User (Value)
        • 7.2.4.1. Hospital
        • 7.2.4.2. Clinic
        • 7.2.4.3. OPDs
        • 7.2.4.4. Others
      • 7.2.5. Global Cancer Anorexia-Cachexia Syndrome Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Cancer Anorexia-Cachexia Syndrome Drug (Price)
      • 7.3.1. Global Cancer Anorexia-Cachexia Syndrome Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Anorexia-Cachexia Syndrome Drug: by Type(USD Million)
  • Table 2. Cancer Anorexia-Cachexia Syndrome Drug NEO-1940 , by Region USD Million (2017-2022)
  • Table 3. Cancer Anorexia-Cachexia Syndrome Drug C-1889 , by Region USD Million (2017-2022)
  • Table 4. Cancer Anorexia-Cachexia Syndrome Drug DLN-101 , by Region USD Million (2017-2022)
  • Table 5. Cancer Anorexia-Cachexia Syndrome Drug Foxo1-nRNA , by Region USD Million (2017-2022)
  • Table 6. Cancer Anorexia-Cachexia Syndrome Drug AVGN-7 , by Region USD Million (2017-2022)
  • Table 7. Cancer Anorexia-Cachexia Syndrome Drug Others , by Region USD Million (2017-2022)
  • Table 8. Cancer Anorexia-Cachexia Syndrome Drug: by Mechanism of Action(USD Million)
  • Table 9. Cancer Anorexia-Cachexia Syndrome Drug Appetite Stimulators , by Region USD Million (2017-2022)
  • Table 10. Cancer Anorexia-Cachexia Syndrome Drug Weight Loss Stabilizers , by Region USD Million (2017-2022)
  • Table 11. Cancer Anorexia-Cachexia Syndrome Drug: by Therapeutics(USD Million)
  • Table 12. Cancer Anorexia-Cachexia Syndrome Drug Progestogens , by Region USD Million (2017-2022)
  • Table 13. Cancer Anorexia-Cachexia Syndrome Drug Megestrol , by Region USD Million (2017-2022)
  • Table 14. Cancer Anorexia-Cachexia Syndrome Drug Corticosteroids , by Region USD Million (2017-2022)
  • Table 15. Cancer Anorexia-Cachexia Syndrome Drug: by End-User(USD Million)
  • Table 16. Cancer Anorexia-Cachexia Syndrome Drug Hospital , by Region USD Million (2017-2022)
  • Table 17. Cancer Anorexia-Cachexia Syndrome Drug Clinic , by Region USD Million (2017-2022)
  • Table 18. Cancer Anorexia-Cachexia Syndrome Drug OPDs , by Region USD Million (2017-2022)
  • Table 19. Cancer Anorexia-Cachexia Syndrome Drug Others , by Region USD Million (2017-2022)
  • Table 20. South America Cancer Anorexia-Cachexia Syndrome Drug, by Country USD Million (2017-2022)
  • Table 21. South America Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 22. South America Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 23. South America Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 24. South America Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 25. Brazil Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 26. Brazil Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 27. Brazil Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 28. Brazil Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 29. Argentina Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 30. Argentina Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 31. Argentina Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 32. Argentina Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 33. Rest of South America Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 34. Rest of South America Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 35. Rest of South America Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 36. Rest of South America Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 37. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Country USD Million (2017-2022)
  • Table 38. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 39. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 40. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 41. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 42. China Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 43. China Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 44. China Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 45. China Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 46. Japan Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 47. Japan Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 48. Japan Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 49. Japan Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 50. India Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 51. India Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 52. India Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 53. India Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 54. South Korea Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 55. South Korea Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 56. South Korea Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 57. South Korea Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 58. Taiwan Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 59. Taiwan Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 60. Taiwan Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 61. Taiwan Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 62. Australia Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 63. Australia Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 64. Australia Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 65. Australia Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 70. Europe Cancer Anorexia-Cachexia Syndrome Drug, by Country USD Million (2017-2022)
  • Table 71. Europe Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 72. Europe Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 73. Europe Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 74. Europe Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 75. Germany Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 76. Germany Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 77. Germany Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 78. Germany Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 79. France Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 80. France Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 81. France Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 82. France Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 83. Italy Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 84. Italy Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 85. Italy Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 86. Italy Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 87. United Kingdom Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 88. United Kingdom Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 89. United Kingdom Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 90. United Kingdom Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 91. Netherlands Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 92. Netherlands Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 93. Netherlands Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 94. Netherlands Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 95. Rest of Europe Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 96. Rest of Europe Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 97. Rest of Europe Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 98. Rest of Europe Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 99. MEA Cancer Anorexia-Cachexia Syndrome Drug, by Country USD Million (2017-2022)
  • Table 100. MEA Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 101. MEA Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 102. MEA Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 103. MEA Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 104. Middle East Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 105. Middle East Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 106. Middle East Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 107. Middle East Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 108. Africa Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 109. Africa Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 110. Africa Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 111. Africa Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 112. North America Cancer Anorexia-Cachexia Syndrome Drug, by Country USD Million (2017-2022)
  • Table 113. North America Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 114. North America Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 115. North America Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 116. North America Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 117. United States Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 118. United States Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 119. United States Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 120. United States Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 121. Canada Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 122. Canada Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 123. Canada Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 124. Canada Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 125. Mexico Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2017-2022)
  • Table 126. Mexico Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2017-2022)
  • Table 127. Mexico Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2017-2022)
  • Table 128. Mexico Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2017-2022)
  • Table 129. Cancer Anorexia-Cachexia Syndrome Drug: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Cancer Anorexia-Cachexia Syndrome Drug: by Type(USD Million)
  • Table 141. Cancer Anorexia-Cachexia Syndrome Drug NEO-1940 , by Region USD Million (2023-2028)
  • Table 142. Cancer Anorexia-Cachexia Syndrome Drug C-1889 , by Region USD Million (2023-2028)
  • Table 143. Cancer Anorexia-Cachexia Syndrome Drug DLN-101 , by Region USD Million (2023-2028)
  • Table 144. Cancer Anorexia-Cachexia Syndrome Drug Foxo1-nRNA , by Region USD Million (2023-2028)
  • Table 145. Cancer Anorexia-Cachexia Syndrome Drug AVGN-7 , by Region USD Million (2023-2028)
  • Table 146. Cancer Anorexia-Cachexia Syndrome Drug Others , by Region USD Million (2023-2028)
  • Table 147. Cancer Anorexia-Cachexia Syndrome Drug: by Mechanism of Action(USD Million)
  • Table 148. Cancer Anorexia-Cachexia Syndrome Drug Appetite Stimulators , by Region USD Million (2023-2028)
  • Table 149. Cancer Anorexia-Cachexia Syndrome Drug Weight Loss Stabilizers , by Region USD Million (2023-2028)
  • Table 150. Cancer Anorexia-Cachexia Syndrome Drug: by Therapeutics(USD Million)
  • Table 151. Cancer Anorexia-Cachexia Syndrome Drug Progestogens , by Region USD Million (2023-2028)
  • Table 152. Cancer Anorexia-Cachexia Syndrome Drug Megestrol , by Region USD Million (2023-2028)
  • Table 153. Cancer Anorexia-Cachexia Syndrome Drug Corticosteroids , by Region USD Million (2023-2028)
  • Table 154. Cancer Anorexia-Cachexia Syndrome Drug: by End-User(USD Million)
  • Table 155. Cancer Anorexia-Cachexia Syndrome Drug Hospital , by Region USD Million (2023-2028)
  • Table 156. Cancer Anorexia-Cachexia Syndrome Drug Clinic , by Region USD Million (2023-2028)
  • Table 157. Cancer Anorexia-Cachexia Syndrome Drug OPDs , by Region USD Million (2023-2028)
  • Table 158. Cancer Anorexia-Cachexia Syndrome Drug Others , by Region USD Million (2023-2028)
  • Table 159. South America Cancer Anorexia-Cachexia Syndrome Drug, by Country USD Million (2023-2028)
  • Table 160. South America Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 161. South America Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 162. South America Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 163. South America Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 164. Brazil Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 165. Brazil Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 166. Brazil Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 167. Brazil Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 168. Argentina Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 169. Argentina Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 170. Argentina Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 171. Argentina Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 172. Rest of South America Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 173. Rest of South America Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 174. Rest of South America Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 175. Rest of South America Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 176. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Country USD Million (2023-2028)
  • Table 177. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 178. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 179. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 180. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 181. China Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 182. China Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 183. China Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 184. China Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 185. Japan Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 186. Japan Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 187. Japan Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 188. Japan Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 189. India Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 190. India Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 191. India Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 192. India Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 193. South Korea Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 194. South Korea Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 195. South Korea Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 196. South Korea Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 197. Taiwan Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 198. Taiwan Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 199. Taiwan Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 200. Taiwan Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 201. Australia Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 202. Australia Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 203. Australia Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 204. Australia Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 206. Rest of Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 207. Rest of Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 208. Rest of Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 209. Europe Cancer Anorexia-Cachexia Syndrome Drug, by Country USD Million (2023-2028)
  • Table 210. Europe Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 211. Europe Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 212. Europe Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 213. Europe Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 214. Germany Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 215. Germany Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 216. Germany Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 217. Germany Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 218. France Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 219. France Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 220. France Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 221. France Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 222. Italy Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 223. Italy Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 224. Italy Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 225. Italy Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 226. United Kingdom Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 227. United Kingdom Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 228. United Kingdom Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 229. United Kingdom Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 230. Netherlands Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 231. Netherlands Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 232. Netherlands Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 233. Netherlands Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 234. Rest of Europe Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 235. Rest of Europe Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 236. Rest of Europe Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 237. Rest of Europe Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 238. MEA Cancer Anorexia-Cachexia Syndrome Drug, by Country USD Million (2023-2028)
  • Table 239. MEA Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 240. MEA Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 241. MEA Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 242. MEA Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 243. Middle East Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 244. Middle East Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 245. Middle East Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 246. Middle East Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 247. Africa Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 248. Africa Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 249. Africa Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 250. Africa Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 251. North America Cancer Anorexia-Cachexia Syndrome Drug, by Country USD Million (2023-2028)
  • Table 252. North America Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 253. North America Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 254. North America Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 255. North America Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 256. United States Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 257. United States Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 258. United States Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 259. United States Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 260. Canada Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 261. Canada Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 262. Canada Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 263. Canada Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 264. Mexico Cancer Anorexia-Cachexia Syndrome Drug, by Type USD Million (2023-2028)
  • Table 265. Mexico Cancer Anorexia-Cachexia Syndrome Drug, by Mechanism of Action USD Million (2023-2028)
  • Table 266. Mexico Cancer Anorexia-Cachexia Syndrome Drug, by Therapeutics USD Million (2023-2028)
  • Table 267. Mexico Cancer Anorexia-Cachexia Syndrome Drug, by End-User USD Million (2023-2028)
  • Table 268. Cancer Anorexia-Cachexia Syndrome Drug: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Anorexia-Cachexia Syndrome Drug: by Type USD Million (2017-2022)
  • Figure 5. Global Cancer Anorexia-Cachexia Syndrome Drug: by Mechanism of Action USD Million (2017-2022)
  • Figure 6. Global Cancer Anorexia-Cachexia Syndrome Drug: by Therapeutics USD Million (2017-2022)
  • Figure 7. Global Cancer Anorexia-Cachexia Syndrome Drug: by End-User USD Million (2017-2022)
  • Figure 8. South America Cancer Anorexia-Cachexia Syndrome Drug Share (%), by Country
  • Figure 9. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug Share (%), by Country
  • Figure 10. Europe Cancer Anorexia-Cachexia Syndrome Drug Share (%), by Country
  • Figure 11. MEA Cancer Anorexia-Cachexia Syndrome Drug Share (%), by Country
  • Figure 12. North America Cancer Anorexia-Cachexia Syndrome Drug Share (%), by Country
  • Figure 13. Global Cancer Anorexia-Cachexia Syndrome Drug: by Type USD/Units (2017-2022)
  • Figure 14. Global Cancer Anorexia-Cachexia Syndrome Drug share by Players 2022 (%)
  • Figure 15. Global Cancer Anorexia-Cachexia Syndrome Drug share by Players (Top 3) 2022(%)
  • Figure 16. Global Cancer Anorexia-Cachexia Syndrome Drug share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Acacia Pharma Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. Acacia Pharma Ltd (United Kingdom) Revenue: by Geography 2022
  • Figure 20. Aeterna Zentaris Inc (United States) Revenue, Net Income and Gross profit
  • Figure 21. Aeterna Zentaris Inc (United States) Revenue: by Geography 2022
  • Figure 22. Aphios Corp (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Aphios Corp (United Kingdom) Revenue: by Geography 2022
  • Figure 24. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 26. Incyte Corp (United States) Revenue, Net Income and Gross profit
  • Figure 27. Incyte Corp (United States) Revenue: by Geography 2022
  • Figure 28. Lakewood-Amedex Inc (United States) Revenue, Net Income and Gross profit
  • Figure 29. Lakewood-Amedex Inc (United States) Revenue: by Geography 2022
  • Figure 30. Obexia AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Obexia AG (Switzerland) Revenue: by Geography 2022
  • Figure 32. PsiOxus Therapeutics Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. PsiOxus Therapeutics Ltd (United Kingdom) Revenue: by Geography 2022
  • Figure 34. RaQualia Pharma Inc (Japan) Revenue, Net Income and Gross profit
  • Figure 35. RaQualia Pharma Inc (Japan) Revenue: by Geography 2022
  • Figure 36. Viking Therapeutics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 37. Viking Therapeutics Inc (United States) Revenue: by Geography 2022
  • Figure 38. Global Cancer Anorexia-Cachexia Syndrome Drug: by Type USD Million (2023-2028)
  • Figure 39. Global Cancer Anorexia-Cachexia Syndrome Drug: by Mechanism of Action USD Million (2023-2028)
  • Figure 40. Global Cancer Anorexia-Cachexia Syndrome Drug: by Therapeutics USD Million (2023-2028)
  • Figure 41. Global Cancer Anorexia-Cachexia Syndrome Drug: by End-User USD Million (2023-2028)
  • Figure 42. South America Cancer Anorexia-Cachexia Syndrome Drug Share (%), by Country
  • Figure 43. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug Share (%), by Country
  • Figure 44. Europe Cancer Anorexia-Cachexia Syndrome Drug Share (%), by Country
  • Figure 45. MEA Cancer Anorexia-Cachexia Syndrome Drug Share (%), by Country
  • Figure 46. North America Cancer Anorexia-Cachexia Syndrome Drug Share (%), by Country
  • Figure 47. Global Cancer Anorexia-Cachexia Syndrome Drug: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Acacia Pharma Ltd (United Kingdom)
  • Aeterna Zentaris Inc (United States)
  • Aphios Corp (United Kingdom)
  • Novartis AG (Switzerland)
  • Incyte Corp (United States)
  • Lakewood-Amedex Inc (United States)
  • Obexia AG (Switzerland)
  • PsiOxus Therapeutics Ltd (United Kingdom)
  • RaQualia Pharma Inc (Japan)
  • Viking Therapeutics Inc (United States)
Select User Access Type

Key Highlights of Report


May 2023 221 Pages 65 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Anorexia-Cachexia Syndrome Drug Quantitative research analysis
Global Cancer Anorexia-Cachexia Syndrome Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Acacia Pharma Ltd (United Kingdom), Aeterna Zentaris Inc (United States), Aphios Corp (United Kingdom), Novartis AG (Switzerland), Incyte Corp (United States), Lakewood-Amedex Inc (United States), Obexia AG (Switzerland), PsiOxus Therapeutics Ltd (United Kingdom), RaQualia Pharma Inc (Japan) and Viking Therapeutics Inc (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Appetite Stimulators are expected to Grow Significantly" is seen as one of major influencing trends for Cancer Anorexia-Cachexia Syndrome Drug Market during projected period 2022-2028.
The Cancer Anorexia-Cachexia Syndrome Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Cancer Anorexia-Cachexia Syndrome Drug Report?

Have a Query? Click Here

Other Related Reports

Glucoamylase Comprehensive Study by Type (Solid State Fermentation, Liquid State Fermentation), Application (Dairy Products, Personal Care, Alcohol Production, Others), Source (Microorganisms (Yeast,...
$ 3800
Epigenetics Drugs Comprehensive Study by Application (Solid Tumors, Liquid Tumors, Inflammatory Diseases, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases), Mechanism of Action (DNMT ...
$ 3450
Urinalysis Test Comprehensive Study by Type (Dipstick Test, Visual Exam, Microscopic Exam), Indication (Urinary Tract Infection, Kidney Stones, Diabetes, Others), Technology (Fully Automated, Semi-au...
$ 3800
Medical Dispatch Solution Comprehensive Study by Application (Hospital, Clinic, Research Institutes, Others), Software (Web-Based, On-premise), Components (Solutions, Services) Players and Region - ...
$ 3800
Neurodegenerative Drugs Comprehensive Study by Route of Administration (Oral, Injection, Transdermal, Others), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), Indication ...
$ 3800
Online Dietary Supplement Comprehensive Study by Type (Vitamins, Minerals, Herbal Products, Amino acids, Botanicals, Sports Nutrition), Application (Pharmaceuticals, Hospitals, Households), Forms (Dr...
$ 3800